Author: Site Editor Publish Time: 13-11-2026 Origin: Site
Pharmaceutical compounds have sparked significant environmental concerns due to their persistence and resistance to biodegradation. Trace pharmaceuticals—such as antibiotics, anti-inflammatory drugs, and psychiatric medications—easily pass through conventional water treatment processes, eventually entering surface waters and even drinking water sources. Water treatment engineers often face a core question: Does UV treatment remove pharmaceuticals from water?
The short conclusion is: Conventional UV treatment alone is not enough. Standard UV disinfection systems are primarily designed to inactivate microorganisms such as bacteria and viruses and generally cannot reliably remove dissolved pharmaceutical compounds. Only a small fraction of UV-sensitive pharmaceuticals can be directly photolyzed, and even then, complete mineralization rarely occurs. To effectively treat pharmaceutical micropollutants, UV is typically combined with advanced oxidation processes (AOPs) using hydrogen peroxide or ozone, alongside multi-barrier treatments like activated carbon and reverse osmosis.
Pharmaceutical wastewater is a global environmental challenge. With increasing human and animal drug consumption, pharmaceutical residues continuously enter aquatic environments through wastewater treatment plants, farms, households, hospitals, and industrial discharges.
Pharmaceuticals are typically categorized as micropollutants and Contaminants of Emerging Concern (CECs). Although concentrations detected in the environment mostly range from the pg/L to µg/L level, they can occasionally exceed mg/L. Their residues and metabolites can impact human health and aquatic ecosystems by:
Promoting the formation of antibiotic-resistant genes and bacteria.
Causing endocrine disruption in aquatic life.
Accumulating in soils, plants, and animals.
Whether a pharmaceutical can be degraded by UV depends primarily on its molar absorption coefficient and quantum yield—its ability to absorb ultraviolet light and the efficiency of the chemical reaction that follows.
Conventional UV treatment faces three key limitations:
Degradation does not equal removal: UV may break down parent pharmaceutical compounds into intermediate byproducts, but it does not necessarily mineralize them completely into carbon dioxide and water. Studies show that even when triclosan and ibuprofen are heavily oxidized, Total Organic Carbon (TOC) and Chemical Oxygen Demand (COD) can remain high, indicating incomplete mineralization.
Water matrix interference: Natural organic matter, nitrates, chlorides, and humic acids absorb or consume light energy and free radicals, reducing degradation efficiency in actual wastewater or surface water.
Dosage and lamp type are critical: Conventional low-pressure UV disinfection doses are typically tailored for pathogen inactivation; degrading pharmaceuticals often requires higher UV doses, medium-pressure UV lamps, or combinations with other oxidants.
The combination of UV and hydrogen peroxide in UV/H2O2 AOP systems is the most mainstream UV-AOP scheme applied in engineering: UVC radiation cleaves H2O2 to generate hydroxyl radicals (·OH), which possess an extremely high oxidation potential. Hydroxyl radicals are non-selective strong oxidants capable of attacking most stable organic structures, making their ability to degrade pharmaceutical micropollutants far superior to UV photolysis alone.
Actual wastewater studies published in Springer (DOI: 10.1007/s11356-025-36547-5) evaluated UV/H2O2 pilot tests across four real water matrices: municipal secondary effluent, graywater, hospital wastewater, and pharmaceutical industrial wastewater, testing over 30 pharmaceuticals and 13 transformation products:
Water matrix complexity dictates performance limits: Under optimal conditions, the total pharmaceutical removal rate reached 69%–86% for municipal secondary effluent, 59% for graywater, 36% for hospital wastewater, and only 17% for pharmaceutical industrial wastewater. More complex wastewater components lead to severe radical scavenging and reduced chemical utility, causing treatment performance to drop sharply.
Categorized by photosensitivity: Photosensitive pharmaceuticals achieved an average removal rate of 93%; moderately photosensitive pharmaceuticals reached 73%; and recalcitrant/resistant pharmaceuticals achieved only 46%. Even with UV-AOP, certain stubborn drugs remain difficult to degrade completely.
Toxicity changes: After UV/H2O2 treatment, the ecotoxicity of municipal sewage, graywater, and hospital wastewater decreased by about 1 toxicity unit. However, pharmaceutical industrial wastewater showed no significant toxicity reduction, indicating that incomplete oxidation leaves toxic transformation byproducts behind—meaning parent compound removal rates alone do not tell the whole story.
Energy consumption variance: The Electrical Energy per Order (EEO) for municipal secondary effluent and graywater ranged from 0.9 to 1.5 kWh/(m³·order); hospital and pharmaceutical wastewaters exhibited significantly higher energy consumption, making upfront economic and energy auditing essential.
Treatment Process | Effect on Pharmaceutical Residues | Main Limitations |
|---|---|---|
Conventional UV Disinfection | Only degrades a few photosensitive drugs (e.g., diclofenac, sulfamethoxazole); most drugs show unstable removal | Designed for disinfection, not chemical pollutant removal; often leaves active degradation byproducts |
UV/H2O2 | Relies on ·OH to broadly enhance degradation of various pharmaceutical micropollutants; top choice for municipal reuse and advanced drinking water treatment | Requires precise hydrogen peroxide dosing; vulnerable to matrix quenching substances, leading to lower efficiency and higher energy use in complex wastewaters |
O3/UV | Exhibits stronger oxidation capabilities against stubborn antibiotics and refractory trace organics | Higher capital and operational costs; relatively rare in large-scale engineering applications |
Activated Carbon / Reverse Osmosis | Physical adsorption or rejection of dissolved pharmaceuticals | Consumables require regular replacement; reverse osmosis produces concentrate, merely transferring rather than destroying pollutants |
In most engineering projects, the safest strategy is not a single device, but a multi-barrier process chain: pretreatment, biological or membrane treatment, Granular Activated Carbon (GAC) or reverse osmosis (RO) systems to remove pollutants, followed by UV or UV/AOP for microbial control and residual micropollutant degradation. Studies show that adsorption combined with advanced oxidation is consistently more effective than standalone technologies.
Upgrading municipal wastewater effluents and supporting water reuse.
Designing pharmaceutical wastewater treatment systems for mixed antibiotic and PPCP pollutants.
Managing emerging trace organic pollutants in drinking water treatment plants.
Situations where concentrate disposal is unavailable, making reverse osmosis undesirable.
Prioritizing the actual destruction of pollutants over mere adsorptive separation.
Standalone UV disinfection cannot reliably remove pharmaceuticals from water, as only a small subset of drugs undergo direct photolysis. UV-AOP advanced oxidation utilizes free radical reactions to broadly degrade various pharmaceutical micropollutants. However, due to significant differences in water matrix characteristics, on-site pilot testing is critical before full-scale implementation to audit energy consumption, oxidant dosage, and byproduct risks. Need help sizing a multi-barrier system for your facility? Contact our water treatment engineers for a customized pilot evaluation.
No. Conventional UV disinfection is designed to inactivate microorganisms like bacteria and viruses, not to remove dissolved chemicals. Only a small fraction of photosensitive drugs (such as diclofenac and sulfamethoxazole) undergo direct photolysis, and they rarely mineralize completely, often leaving behind active or toxic transformation byproducts.
UV Advanced Oxidation Processes (UV-AOP), such as combining UVC light with hydrogen peroxide (UV/H2O2), split H2O2 to generate hydroxyl radicals (·OH). These non-selective, highly reactive oxidants break down stubborn pharmaceutical molecular structures far more effectively than standalone UV photolysis.
Removal efficiency depends heavily on water matrix complexity. Under optimal conditions, UV/H2O2 achieves 69%–86% total pharmaceutical removal in municipal secondary effluent and 59% in graywater. However, efficiency drops to 36% in hospital wastewater and 17% in complex pharmaceutical industrial wastewater due to radical scavenging.
The most reliable engineering approach combines multiple treatment barriers rather than relying on a single technology. A typical multi-barrier train includes pretreatment, biological or membrane filtration, Granular Activated Carbon (GAC) adsorption or Reverse Osmosis (RO), followed by UV or UV/AOP for final disinfection and micropollutant degradation.
